

11-14-01  
DT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBL ET AL.

APPLICATION NO: NOT ASSIGNED YET

FILED: HEREWITH

FOR: METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING  
AN AP2 INHIBITOR AND COMBINATION

FOE#20-3322-024

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Kindly amend the above-referenced application as follows:

In the Specification:

Page 1, line 3, please insert the following:

(A) --This application is a continuation of U.S. Serial No. 09/390,275 filed September 7, 1999, which claims priority from U.S. Provisional Application Serial No. 60/100,677. The entirety of each of these applications is incorporated herein by reference.--

(A) 2 Page 3, please replace the paragraph beginning at line 1 and ending at line 16 with the following:

--The aP2 inhibitors suitable for use in the method of the invention are compounds which bind to the aP2 protein (SEQ ID NO:1) and inhibits its function and/or its ability to bind free fatty acids. The compounds will preferably contain less than 60 carbon atoms, more preferably less than 45 carbon atoms, and will contain less than 20 heteroatoms, more preferably less than 12 heteroatoms. They contain a hydrogen bond donor or acceptor group, preferably acidic in nature, which includes, but is not limited to, CO<sub>2</sub>H, tetrazole, SO<sub>3</sub>H, PO<sub>3</sub>H, P(R)(O)OH (where R is lower